Methods of making ureas and guanidines, including, terazosin, prazosin, doxazosin, tiodazosin, trimazosin, quinazosin, and bunazosin (exemplary of 2- substituted quinazoline compounds), and meobentine, and bethanidine and intermediates therefor

ABSTRACT

Novel methods for the synthesis of substituted ureas and guanidines including Terazosin, Prazosin, Doxazosin, Tiodazosin, Trimazosin, Quinasin and Bunazosin (exemplary of 2-amino substituted Quinazolines), Meobentine and Bethanidine and novel intermediates suitable for use in such methods of synthesis are taught.

This application is a divisional of application Ser. No. 08/004,114filed Jan. 13, 1993 now abandoned.

FIELD OF INVENTION

This invention relates to novel processes of making ureas for exampleN-monosubstituted, N-N-disubstituted, N,N-N'-trisubstituted, N,N-N',N'-tetrasubstituted ureas and guanidines and derivatives thereof. Anumber of such compounds comprise 2-amino-substituted quinazolines (suchas terazosin, prazosin, tiodazosin, bunazosin, quinazosin and trimazosinand doxazosin) and other guanidines (such as Meobentine and Bethanidine)which are known medicaments known to reduce blood pressure inhyperactive subjects.

This invention also relates to a number of novel intermediates(including novel ureas and novel guanidines) that may be used in thesynthesis of for example the 2-amino-substituted quinazolines andguanidines and the methods of the synthesis thereof.

Some of these novel intermediates that are guanidines may also be usefulas accelerators in the manufacture of rubber and as activators forthiazole accelerators.

BACKGROUND OF THE INVENTION

A number of medicines are guanidines. These guanidines include cyclizedguanidines of the general formula 1.

    ______________________________________                                         ##STR1##                                                                     COMPOUND R      R.sub.1                                                                             R.sub.2                                                                           n   R.sub.3                                         ______________________________________                                        PRAZOSIN H      Me    Me  1                                                                                  ##STR2##                                       TERAZOSIN                                                                              H      Me    Me  1                                                                                  ##STR3##                                       DOXAZOSIN                                                                              H      Me    Me  1                                                                                  ##STR4##                                       TIODAZOSIN                                                                             H      Me    Me  1                                                                                  ##STR5##                                       TRIMAZOSIN                                                                             OMe    Me    Me  1                                                                                  ##STR6##                                       QUINAZOSIN                                                                             H      Me    Me  1                                                                                  ##STR7##                                       BUNAZOSIN                                                                              H      Me    Me  2                                                                                  ##STR8##                                       Thus they include the following cyclized guanidines of general formula         ##STR9##                                                                      ##STR10##                                                                     ##STR11##                                                                     ##STR12##                                                                    ______________________________________                                    

Thus they include the following cyclized guanidines of general formula2.

The following compounds are exemplary: ##STR13## These guanidines alsoinclude uncyclized guanidines of the general formula 3. ##STR14##wherein Me is CH₃ (methyl).

The prior art preparations of cyclized and uncylized guanidines forexample of Terazosin (R₃ =tetrahydrofuryl), Prazosin (R₃ =furyl),Doxazosin (R₃ =1,4,-benzodioxan-2-yl), and Meobentine (R'₁-4-methoxybenzyl, R'₂ =H, R'₃ =methyl, R'₄ =H, R'₅ =CH₃) are discussedbelow.

Compounds of general formula 2 have been prepared by a number ofapproaches which may be classified into five general methods.

In method 1, a 4-amino-6,7-dimethoxy quinazoline that is substituted atC-2 position with a good leaving group X, is condensed with a properamine. Up to nine steps are used to synthesize the 4-amino-6,7-dimethoxyquinazoline, starting from veratraldehyde J. Chem. Soc. 1759, (1948) andJ. Med. Chem. 20, 146, (1977)!.

    ______________________________________                                        METHOD 1                                                                       ##STR15##                                                                     ##STR16##                                                                    X              Reference                                                      ______________________________________                                        Cl             Fr. Pat. 2321890                                                              Fr. Pat. 2350101                                                              Can Pat. 1057754                                                              Can Pat. 1081229                                                              Ger Pat. 2707068                                                              Ger Pat. 2725019                                                              Eur Pat. 0034471                                                              U.S. Pat.                                                                              4251532                                                              U.S. Pat.                                                                              4026894                                                              Brit Pat.                                                                              1156973                                                              Brit Pat.                                                                              2021108                                               SCH.sub.3      Ger Pat. 2707068                                                              Brit Pat.                                                                              1156973                                                              Brit Pat.                                                                              2021108                                               SO.sub.2 alkyl Brit Pat.                                                                              2021108                                               ______________________________________                                    

Those fine chemical manufacturers synthesizing prazosin, terazosin, anddoxazosin for the most part use this process or a modification thereof.The major shortcoming of this method (method 1) is the low yields(between about 5 and 25%) which may be ascribed to the large number ofsteps involved.

In method 2, a 3,4-dimethoxyaniline that is substituted at the C-6position with a nitrile, amide or amidine group is condensed with anamine that is N-substituted with an appropriate functional group, Y.

    ______________________________________                                        METHOD 2                                                                       ##STR17##                                                                     ##STR18##                                                                    C-6(Z)       Y              Reference                                         ______________________________________                                        CN           CN             Brit Pat. 1390014                                                             Brit Pat. 1390015                                                             Eur Pat. 0034471                                  CN           H.sub.2 NCNH   Brit Pat. 1156973                                 CN           H.sub.2 NCNH   Brit Pat. 1156973                                 (C1 instead of NH.sub.2 at                                                    C-1 position)                                                                 CN           HNCO-Alkyl     Ger Pat. 2457911                                  CN           HNCS-Alkyl     Ger Pat. 2457911                                  OCNH.sub.2   CN             Ger Pat. 2457911                                  HNCNH.sub.2  CN             Ger Pat. 2457911                                  ______________________________________                                    

The processes taught by German Patent 2457911 propose the use of highlytoxic cyanogen bromide. The yields of the processes are poor at best andthus not attractive for commercial production.

In method 3, 3,4-dimethoxy-6-cyanoaniline is converted to itscorresponding isothiocyanate using thiophosgene. This is then condensedwith a proper amine. The resulting thiourea is then S-alkylated (e.g.methyl iodide). High temperature reflux in the presence of ammoniumchloride results in the insertion of the amine group, followed by ringclosure to afford Terazosin (Bel. Pat. PCT/F18200034, Eur. Pat.0034471). However thiophosgene is extremely toxic and its use is notpractical on commercial scale due to high cost and limited availability.##STR19##

In method 4, N-cyano-N-(3,4-dimethoxyphenyl)-5-methylisothiourea see J.Heterocycl. Chem. 23, 401 (1986) or Hungarian Pat. 181743! is condensedwith a proper amine to afford a carboxamidine which upon heating at hightemperature affords the desired product (Can. Pat. 2015066, Eur. Pat.0034471). The reported yields starting from the thioether is 63%.However, the thioether itself is difficult to manufacture. ##STR20##

In method 5, 2-chloro-4-amionquinazoline is initially condensed withpiperazine and the resulting amine is reacted with an acid chloride toafford the desired product (Brit. Pat. 1156973). ##STR21##

As in method 1, this process also fails to provide good yields, becauseof the number of steps involved in the preparation of the2-chloroquinazoline starting material.

These methods suffer from various other shortcomings. For example, theuse of 2-chloro-4-amino-6,7-dimethoxyquinazoline (method 1 and 5) isprohibitive due to the fact its synthesis involves nine steps fromveratraldehyde and the overall yield is approximately 5-25% F. H. S.Curd et. al., J. Chem. Soc. 1759 (1948) and J. Med. Chem. 20, 146(1977)!.

Activation of the amine group (method 2) requires the use of highlytoxic cyanogen bromide (Y=CN), followed by further modification of theactivating group (Y═H₂ N--C═NH, HN═C--O--Alkyl). Use of ammoniumthiocyanate, followed by alkylation of sulfur, will result inY═HN═C--S--Alkyl. Nevertheless, the yields are generally low (ca. 40%).In method 3, although the reported yield of prazosin is high (ca. 68%),high toxicity and limited commercial availability of thiophosgenerenders the method unattractive. In method 4, the overall yield startingfrom N-cyano N'-((3,4-dimethoxyphenyl)-S-methyl-isothiourea is reportedto be ca. 63%. Nevertheless, the requirement of this isothiourea asstarting material the preparation of which being very difficult andinefficient, renders the method unattractive.

Compounds of general formula 3 are synthesized using S-alkylatedthiourea and the corresponding amine. The synthesis of Meobentine hasbeen reported is U.S. Pat. No. 3,949,089 as described below: ##STR22##

The use of thiophosgene to manufacture thiourea is limited due to itshigh toxicity and commercial unavailability. Use of ammonium thiocyanateon the other hand followed by alkylation of the resulting thioureagenerally affords low overall yields and therefore suffers from the samedisadvantages described in the methods 2 and 3 (vide supra).

It is therefore an object of this invention to provide improved moreefficient methods for the synthesis of compounds such as ureas andguanidines for example cyclized guanidines such as 2-amino substitutedquinazolines of general formula 1 (e.g. Terazosin, Prazosin, Doxazosin,Tiodazosin, Trimazosin, Quinasin and Bunazosin) and for exampleuncyclized guanidines such as those of general formula 3 (e.g.Meobentine and bethanidine).

It is a further object of the invention to provide such improved moreefficient processes which produce the desired compounds for exampleguanidines and ureas and in higher yields than in the prior art.

It is still a further object of the invention to provide such compoundsfor example quinazolines of very high purity (therefore having thedesired efficacy).

It is still further object of this invention to provide (manufacture)novel intermediates including ureas and guanidines suitable for use tosynthesize other guanidines for example 2-amino-substituted quinazolinesincluding Terazosin, Prazosin, and Doxazosin and other guanidines forexample meobentine and Bethanidine.

Further and other objects of the invention will be realized by thoseskilled in the art from the following summary of the invention anddetailed description of the embodiments thereof.

SUMMARY OF THE INVENTION

According to one aspect of the invention a method of manufacture ofcompounds such as ureas and guanidines including cyclized guanidines forexample 2-amino-substituted quinazolines compounds (for exampleTerazosin, Prazosin, Doxazosin, Tiodazosin, Trimazosin, Quinasin andBunazosin) and for example uncylized guanidines such as meobentine andBethanidine are provided, comprising:

(a) (i) adding oxygen or a hetero radical containing oxygen to anintermediate compound for example by adding a carbonyl (c) to an aminein one embodiment in a form of converting an amine to its correspondingurea or

(ii) starting with an intermediate compound containing oxygen forexample containing a carbonyl group in some embodiments connected to anamine or forming part of a urea,

and (b) carrying out in any order (i) or (ii) of this subparagraph (b)

(i) react the oxygen for example the oxygen of a carbonyl, with asuitable electrophile (EP) in which the combination of theoxygen-electrophile (O--EP) becomes a good leaving group that can be andis subsequently displaced by for example a nucleophile (such as forexample ammonia or an amine) and

(ii) adding a desired radical to the results of subparagraph (a) or b(i) if step (i) of subparagraph (b) is carried out before this step(ii), and

(c) optionally, and if required, closing a ring to form for example a2-amino-substituted quinazoline.

Other guanidines including quinazolines may also be manufacturedaccording to the invention as would be understood by persons skilled inthe art.

According to another aspect of the invention the desired radical isammonia or an amine radical.

In this way, greater yields and higher purity in the manufacture ofknown products can be achieved. Furthermore compounds of the inventionmay be conveniently prepared by a "one pot" synthesis.

EP is preferably POCl₃. EP may also comprise: PCl₅, P₂ O₅, tosylchloride (CH₃ SO₂ Cl)--TsCl-- and in some instances mesyl chloride (CH₃SO₂ Cl)--MsCl--.

Thus according to another aspect of the invention, such a methodcomprises;

a) taking a known intermediate and adding oxygen or a hetero radicalcontaining oxygen to it for example by adding a carbonyl (c) to anamine;

b) adding a desired radical to the results of (a);

c) adding a suitable electrophile (EP) to react with the oxygen to yielda reaction product (O--EP) which is a leaving group susceptible toreplacement by a nucleophile such as ammonia or an amine;

d) replacing the reaction product (leaving group) of (c) with NH₂ or anamine group;

e) closing a ring if required to produce a desired compound.

In accordance with another aspect of the invention, such a method maycomprise;

f) taking an intermediate compound carrying oxygen (for example theresults of subparagraph (a) of the previous paragraph) and adding asuitable electrophile (EP) to react with the intermediate at the site ofthe oxygen to yield a reaction product therebetween as a leaving groupsusceptible to replacement by a nucleophile such as ammonia or amine;

g) replacing the reaction product (O--EP) (leaving group) of (f) withNH₃ or ammonia group;

h) optionally adding a radical if desired before or after carrying outeither or both of steps (f) and (g);

i) closing a ring if required to produce a desired compound.

According to another aspect of the invention a method of manufacture ofsubstituted ureas and guanidines including 2-amino-substitutedquinazoline compounds (for example Terazosin, Prazosin and Doxazosin) isprovided comprising;

(a) converting an amine to its corresponding urea;

substituting the NH₂ group of the substituted urea of (a) by an amine;

(c) reacting the resulting substituted urea with a suitable electrophile(EP) to yield a reaction product in which the oxygen of the urea reactswith the electrophile (EP) to become a good leaving group that can bedisplaced by a nucleophile for example such as ammonia or an amine;

(d) replacing the reaction product between the oxygen and EP (leavinggroup) of (c) by NH₃ or an amine to provide for example unsymmetricallysubstituted guanidines;

(e) optionally, and if required closing the resulting substitutedguanidine to provide 2-amino-substituted quinazolines such as Terazosin,Prazosin, and Doxazosin.

In this way, greater yields and high purity of known products can beachieved, for example steps (a) and (b) of the immediately previousprocess being both converted in very high yields of 85-95%. Furthermorecompounds of the invention may be conveniently prepared by a "one pot"synthesis, starting from the substituted urea (b).

According to another aspect of the invention, such a method maycomprise;

a) taking a known intermediate and converting it to a urea;

b) adding a suitable electrophile (EP) to react with the oxygen of theurea to yield a reaction product as a leaving group susceptible toreplacement by an amine;

c) replacing the leaving group of (b) with an amine;

d) closing a ring if required to produce a desired compound.

In accordance with another aspect of the invention, such a method maycomprise;

e) taking a known intermediate and converting it to a urea;

f) adding a suitable electrophile (EP) to react with the oxygen of theurea to yield a reaction product as a leaving group susceptible toreplacement by an amine;

g) displacing the leaving group of the reaction product of (f) with anamine;

h) closing the ring if required to produce a desired compound.

The salts of the guanidines may also be produced for example Terazosinhydrochloride and terazosin hydrochloride dihydrate and DoxazosinMesylate.

In accordance with another aspect of the invention, exemplary novelprocesses of the manufacture of guanidine compounds are disclosed. Inone method, guanidine compounds are synthesized starting for examplefrom 3,4-dimethoxyanthranilonitrile I and the corresponding amine III.The initial reactants are all available and are easily manufactured aswould be understood by persons skilled in the art.

In an exemplary method, an amine I (nitrile) is converted to itscorresponding urea II in high yields (85-90%) with sodium cyanate. Theresulting urea is then condensed with a proper amine IIIN-(tetrahydro-2-furoyl) piperazine in the case of Terazosin,N-(2-furoyl) piperazine in the case of Prazosin,N-(1,4-Benzodioxan-2-carbonyl) piperazine in the case of Doxazosin,Methylthiooxadiazale carbonyl piperazine in the case of Tiodazosin,2,2-dimethyl-2-hydroxy ethyl ester piperazine in the case of Trimazosin,propene carbonyl piperazine in the case of Quinazosin and butyroyl diazocycloheptane (a 7-membered dinitrogen radical) in the case of bunazosin!in refluxing pyridine to afford IV (85-95% yield). The intermediate IVis then reacted with an appropriate electrophile (e.g. POCl₃, PCl₅,tosyl chloride, phosphorous pentoxide), resulting in the conversion ofthe oxygen of the urea into a good leaving group (V). Addition ofammonia (e.g. ammonia gas or ammonium carbonate) will then displace theactivated oxygen function, forming the corresponding guanidine VI.Quinazoline ring system VII is then formed by the attack of the aminogroup of the guanidine on the nitrile. This is a very facile reactionand in fact intermediate VI was not isolated.

The following reaction scheme thus presents itself: ##STR23## wherein--O--EP is the reaction of the urea oxygen and EP, and is a leavinggroup substitutable by --NH₂ or an amine.

In this scheme R may be hydrogen or lower alkoxy (for example methoxy),R₁ and R₂ may be lower alkyl (for example methyl), n is a numberselected from 1 and 2 and R₃ may be selected from unsubstituted orsubstituted furoyl (for example furoyl or tetrahydrofuroyl),benzodioxanyl carbonyl (for example 1,4-benzodioxan-2-yl carbonyl),lower alkylthiooxadiazole carbonyl (for example methylthiooxadiazolecarbonyl), dialkyl hydroxy alkyl ester (for example 2,2-dimethyl hydroxyethyl ester), alkene (for example propene) and alkyroyl (for examplebutyroyl).

The following chart identifies combinations of substituents foridentified Medicines:

    ______________________________________                                        COMPOUND R      R.sub.1                                                                             R.sub.2                                                                           n   R.sub.3                                         ______________________________________                                        PRAZOSIN H      Me    Me  1                                                                                  ##STR24##                                      TERAZOSIN                                                                              H      Me    Me  1                                                                                  ##STR25##                                      DOXAZOSIN                                                                              H      Me    Me  1                                                                                  ##STR26##                                      TIODAZOSIN                                                                             H      Me    Me  1                                                                                  ##STR27##                                      TRIMAZOSIN                                                                             OMe    Me    Me  1                                                                                  ##STR28##                                      QUINAZOSIN                                                                             H      Me    Me  1                                                                                  ##STR29##                                      BUNAZOSIN                                                                              H      Me    Me  2                                                                                  ##STR30##                                      ______________________________________                                    

Thus the following is specifically included: ##STR31##

The radical R₃ ' and R₃ '-C may be substituted by other radicals as isapparent from examination of the substituents for R₃ '.

Usual work up of the reaction mixture results in the isolation of thedesired product. Compounds II (including II'), IV (including IV'), V(including V') and VI (including VI') are novel and the processes oftheir manufacture are also novel.

In the case of Meobentine and Bethanidine, urea Ia, for example,dimethyl urea, is reacted with Electrophile (EP) to produce (IIa).Condensation of benzylamine (IIIa) with IIa affords Meobentine andBethanidine. ##STR32## Compounds IIa are new and the processes of theirmanufacture are also novel.

In another method, for example the urea nitrile II is initiallyactivated with an electrophile (EP) such as POCl₃, PCl₅, etc, (seeabove) to form intermediate VIII in which the oxygen function of theurea reacted with the EP becomes a good leaving group. Displacement ofthe oxygen by a proper amine III and subsequent work-up results in theisolation of the desired quinazoline VII (for example terazosin).Compounds II, VI and VIII are novel. Preferably EP is PCOl₃.

The following reaction scheme presents itself:

    __________________________________________________________________________     ##STR33##                                                                     ##STR34##                                                                    wherein                                                                              R    R.sub.1                                                                          R.sub.2                                                                         n    R.sub.3        are selected from                        __________________________________________________________________________           H    Me Me                                                                              1                                                                                   ##STR35##                                                     H    Me Me                                                                              1                                                                                   ##STR36##                                                     H    Me Me                                                                              1                                                                                   ##STR37##                                                     H    Me Me                                                                              1                                                                                   ##STR38##                                                     OMe  Me Me                                                                              1                                                                                   ##STR39##                                                     H    Me Me                                                                              1                                                                                   ##STR40##                                              and    H    Me Me                                                                              2                                                                                   ##STR41##                                              __________________________________________________________________________

Thus the following is specifically included: ##STR42## (Thetetrahydrofuryl radical may be substituted by furyl or1,4-benzodioxan-2-yl to produce Prazosin and Doxazosin, respectively.The tetrahydrofuryl radical, tetrahydrofuroyl radical, andtetrahydrofuroyl piperazine radical may also be substituted by the otherradicals for example those for R₃ '.)

In another method, for example the amine III is converted to itscorresponding urea IX with cyanic acid. Again the oxygen function of theurea is converted to a good leaving group using an electrophile (EP)such as POCl₃, PCl₅, etc. to form X. Displacement of the activatedoxygen by the amine function of I and subsequent work-up results in theisolation of the desired quinazoline VII, which may be converted to itspharmaceutically acceptable salts (for example the hydrochloride ormesylate salt). The following reaction scheme presents itself:

    __________________________________________________________________________     ##STR43##                                                                     ##STR44##                                                                    wherein                                                                              R    R.sub.1                                                                           R.sub.2                                                                          n     R.sub.3        are selected from                     __________________________________________________________________________           H    Me  Me 1                                                                                    ##STR45##                                                  H    Me  Me 1                                                                                    ##STR46##                                                  H    Me  Me 1                                                                                    ##STR47##                                                  H    Me  Me 1                                                                                    ##STR48##                                                  OMe  Me  Me 1                                                                                    ##STR49##                                                  H    Me  Me 1                                                                                    ##STR50##                                           and    H    Me  Me 2                                                                                    ##STR51##                                           __________________________________________________________________________

Compounds IX, X and VI are novel and processes of their manufacture arealso novel.

Thus the following is included: ##STR52##

(Once again the tetrahydrofuryl radical may be replaced by furyl or1,4-benzodioxan-2-yl). The tetrahydrofuryl radical and thetetrahydrofuroyl radicals may also be substituted as is apparent.

Compounds VI", IX" and X" are novel and the processes of theirmanufacture are also novel.

Thus according to another aspect of the invention, compounds of theformula ##STR53## are provided wherein R_(a) is selected from hydrogen,R_(b) is selected from hydrogen, and a substituted phenyl radicalsubstituted by at least one of alkoxy (for example methoxy) and cyano,and

R_(c) and R_(d) are each selected from hydrogen, (provided R_(c) andR_(d) are not hydrogen when R_(a) and R_(b) are hydrogen) or may withthe nitrogen be connected together to form a closed ring preferablycontaining at least a second nitrogen, (preferably being a 6-membered or7-membered ring), the closed ring being substituted by substitutedcarbonyl for example R carbonyl (wherein R is selected from furyl,tetrahydrofuryl, 1,4-benzodioxan-2-yl, alkylthiooxadiazole for examplemethylthiooxadiazole and alkyl (for example propyl), dialkyl hydroxyalkyl ester for example, 2,2-dimethyl-2-hydroxy-ethyl ester, and alkene(for example propene).

Exemplary of such compounds are II, II', IV, IV", IX and IX" set outbelow: ##STR54##

According to another aspect of the invention compounds of the formula##STR55## are provided, wherein: EP is an electrophile and together withthe oxygen forms a leaving group wherein --O--EP is the reaction of theurea oxygen and EP, and is leaving group substitutable by --NH₂ orammonia (preferably substitutable by NH₂ or an amine) (preferably EPbeing selected from POCl₃, P₂ O₅, PCl₅, mesyl chloride and tosylchloride),

R_(b) is selected from hydrogen, alkyl (for example methyl) and asubstituted phenyl radical substituted by at least one of alkoxy (forexample methoxy) and cyano, and R_(c) and R_(d) are each selected fromhydrogen, lower alkyl (for example methyl) a substituted phenyl radicalsubstituted by at least one alkoxy (for example methoxy) and cyano ormay with the nitrogen be connected together to form a closed ringpreferably containing at least a second nitrogen, (preferably being a6-membered or 7-membered ring), the closed ring being substituted byR-carbonyl (wherein R is selected from for example furyl,tetrahydrofuryl, 1,4-benzodioxan-2-yl, akylthiooxadiazole, for examplemethylthiooxadiazole, alkyl for example propyl, dialkyl hydroxy alkylester for example 2,2-dimethyl-2-hydroxy-ethyl ester and alkene (forexample propene). Exemplary of such compounds are V, V', IIa, VIII,VIII', X and X" set out below: ##STR56##

According to another aspect of the invention compounds of formula##STR57## are provided wherein R_(b) is selected from a substitutedphenyl being substituted by a radical selected from at least one ofalkoxy (for example methoxy) and cyano and R_(c), R_(d) together withthe Nitrogen, form a closed ring preferably containing a second nitrogen(preferably being a 6-7 membered ring), the closed ring beingsubstituted by furoyl, tetrahydrofuroyl, 1,4-benzodioxan-2-yl carbonyl,methylthiooxadiazole carbonyl, dialkyl hydroxy alkyl ester (for example2, 2-dimethyl-2-hydroxy-ethyl ester), alkene (for example propene),alkoyl (for example butyroyl)

Exemplary of such compounds are compounds V, VI' and VI" set out below:##STR58##

Additionally compounds VII and XI are of higher purity than prior artcompounds and contain for example residues of II, IV, V, VI, VIII, IX orX. ##STR59## wherein the appropriate substituents are selected dependenton the medicine for example see the chart below:

    ______________________________________                                        COMPOUND R      R.sub.1                                                                             R.sub.2                                                                           n   R.sub.3                                         ______________________________________                                        PRAZOSIN H      Me    Me  1                                                                                  ##STR60##                                      TERAZOSIN                                                                              H      Me    Me  1                                                                                  ##STR61##                                      DOXAZOSIN                                                                              H      Me    Me  1                                                                                  ##STR62##                                      TIODAZOSIN                                                                             H      Me    Me  1                                                                                  ##STR63##                                      TRIMAZOSIN                                                                             OMe    Me    Me  1                                                                                  ##STR64##                                      QUINAZOSIN                                                                             H      Me    Me  1                                                                                  ##STR65##                                      BUNAZOSIN                                                                              H      Me    Me  2                                                                                  ##STR66##                                      ______________________________________                                    

The combinations of these residues with VII and XI are also newproviding a product of higher purity. Thus for example for Terazosin,the residues II', IV", V", VI", VIII', IX" and/or X" are follows:##STR67## wherein --O--EP is the reaction of the urea oxygen and EP, andis a leaving group substitutable by --NH₂ or ammonia.

Where the medicine is Prazosin the residues II', IV'", V'", VI'", VIII',IX'" and/or X'" may be: ##STR68## wherein --O--EP is the reaction of theurea oxygen and EP, and is a leaving group substitutable by --NH₂ orammonia.

Where the medicine is doxazosin the residues II', IV', V', VI', VII',IX' and/or X' may be: ##STR69## and wherein --O--EP is the reaction ofthe urea oxygen and EP, and is a leaving group substitutable by --NH₂ orammonia.

In respect of the medicines Tiodazosin, Trimazosin, Quinasin andBunazosin, the residues are II, IV, V, VI, VIII, IX and/or X ##STR70##wherein --O--EP is the reaction of the urea oxygen and EP, and is aleaving group substitutable by --NH₂ or ammonia wherein for themedicine:

(a) TIODAZOSIN

R is H

R₁ is Methyl

R₂ is Methyl

n is 1

and R₃ is ##STR71##

(b) TRIMAZOSIN

R is methoxy (OMe)

R₁ is Methyl

R₂ is Methyl

and R₃ is ##STR72##

(c) QUINAZOSIN

R is hydrogen

R₁ is Methyl

R₂ is Methyl

and R₃ is ##STR73##

(d) BUNAZOSIN

R is hydrogen

R₁ is Methyl

R₂ is Methyl

and R₃ is ##STR74## Where the medicine is Meobentine or Bethanidine, theresidue includes IIa. ##STR75##

Thus the combinations of the above medicines with at least one of theassociated residues is new and provides medicine having a very highpurity.

The invention will now be illustrated with respect to the followingexemplary methods of manufacture.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION EXAMPLE 13,4-Dimethoxy-6-cyanoaniline-1-ylformamide (II)

3,4-Dimethoxyanthraniloniltrile (300 g, 1.69 mol) is taken in glacialacetic acid (1500 mL) and cooled to +5° C. To this solution is added asuspension of sodium cyanate (160.5 g, 2.46 mol in 750 mL of deionizedwater) in 100 mL portions over a thirty minute period. Acetone (6000 mL)is added and the mixture is maintained at +5° C. for an additional 30minutes. The product is filtered and the cake is washed with acetone(2×150 mL) (293/7 grams, 79% yield).

¹ H nmr (DMSO-d₆) d 8.19 (bs, 1H, NH); 7.48 (s, 1H, C-5); 6.98 (s, 1H,C-2); 6.12 (bs, 2H, NH₂); 3.65 (s, 3H, OCH₃); 3.60 (s, 3H, OCH₃).

EXAMPLE 2 4-(2-tetrahydrofuroyl)piperazine-1-ylformamide (IX)

4-(2-Tetrahydrofuroyl)piperazine (33.25 g, 180.7 mmol) (III) isdissolved in 165 mL water. 5N Hydrochloric acid (34.5 mL) is added andthe suspension is heated to 70° C. with stirring. Sodium cyanate (13.1g, 201.15 mmol) is added in small portion to the stirring solution andheating is continued for an additional 2 hours. The reaction mixture isconcentrated under reduced pressure to yield a thick oil. Chloroform(100 mL) is added to the off and the solution is heated to reflux. Thehot solution is filtered and the filtrate is dried over Na₂ SO₄. Thedried solution is concentrated under reduced pressure to a thick yellowoil. Ether (50 mL) is added to the oil and white crystals precipitatedout. The product is filtered, washed with ether (25 mL) and dried. Theproduct is used without further purification (33.8 g, 82.3% yield).

¹ H nmr (CDCl₃) d 5.60 (bs, 2H, NH₂); 4.32 (t, J=7.0 Hz, 1H, CH, C-2(tetrahydrofuroyl)); 3.80 (t, J=6.0 Hz, 2H, CH₂, C-5(tetrahydrofuroyl)); 3.70-2.80 (m, 8H, CH₂ 's (C-2, C-3, C-5, C-6(piperazinyl))); 2.39-1.49 (m, 4H, CH₂ 's (C-3, C-4 (tetrahydrofuroyl)).

EXAMPLE 3 3,4-dimethoxy-6- 4-(2-tetrahydrofuroyl)piperazine-1-ylcarbamidol! benzonitrile (IV)

3,4-Dimethoxy-6-cyanoaniline-1-ylformamide (2.75 g, 12.5 mmol) (II) and4-(2-tetrahydrofuroyl) piperazine (2.56 g, 13.9 mmol) (III) aresuspended in 25 mL dry pyridine and the mixture is refluxed for 3 hours.The solvent is then vacuum distilled to a minimum volume and thenazeotroped with small portions of water. The final aqueous solution isextracted with six portions (20 mL) of ethyl acetate. The organic layeris concentrated and applied to a silica gel column (25 cm×2.5 cm). It isthen eluted with ethyl acetate initially and the polarity is graduallyincreased with ethanol to a final solvent ratio of 80:20. Fractionscontaining the product (TLC: 80:20 ethylacetate:methanol, R_(f) =0.5)are combined and the solvent evaporated. The pure product iscrystallized from a small volume of ethyl acetate as light yellowneedles (4.27 g, 85% yield).

¹ H nmr (CDCl₃) d 7.35 (s, 1H, ArH, C-2); 7.10 (bs, 1H, NH; 6.85 (s, 1H,ArH, C-5); 4.58 (t, J=7.0 Hz, 1H, CH, C-2 (tetrahydrofuroyl)); 3.89 (s,3H, OCH₃); 3.80 (s, 3H, OCH₃); 4.11-3.18 (m, 10H, CH₂ 's (C-2, C-3, C-5,C-6 (piperazinyl), C-5 (tetrahydrofuroyl))); 2.22-1,49 (m, 4H, CH₂ 's(C-3, C-4 (tetrahydrofuroyl))).

EXAMPLE 4 3,4-dimethoxy-6-4-(2-tetrahydrofuroyl)piperazine-1-ylcarbamido!benzonitrile(IV)

3,4-Dimethoxy-6-cyanoaniline-1-ylformamide (2.75 g, 12.5 mmol) (lI) and4-(2-tetrahydrofuroyl)piperazine (2.56 g, 13.9 mmol) (III) are suspendedin 25 mL dry dimethylformamide and the mixture is refluxed for 3 hours.The solvent is then vacuum distilled to a minimum volume and thenazeotroped with small portions of water. The final aqueous solution isextracted with six portions (20 mL) of ethyl acetate. The organic layeris concentrated and applied to a silica gel column (25 cm×2.5 cm). It isthen eluted with ethyl acetate initially and the polarity is graduallyincreased with ethanol to a final solvent ratio of 80:20. Fractionscontaining the product (TLC: 80:20 ethylacetate:methanol, R_(f) =0.5)are combined and the solvent evaporated. The pure product iscrystallized from a small volume of ethyl acetate as light yellowneedles (2.85 g, 60% yield).

¹ nmr (CDCl₃) d 7.35 (s, 1H, ArH, C-2); 7.10 (bs, 1H, NH; 6.85 (s, 1H,ArH, C-5); 4.58 (t, J=7.0 Hz, 1H, CH, C-2 (tetrahydrofuroyl)); 3.89 (s,3H, OCH₃); 3.80 (s, 3H, OCH₃); 4.11-3.18 (m, 10H, CH₂ 's (C-2, C-3, C-5,C-6 (piperazinyl), C-5 (tetrahydrofuroyl))); 2.22-1.49 (m, 4H, CH₂ 's(C-3, C-4 (tetrahydrofuroyl))).

EXAMPLE 5 3,4-dimethoxy-6-4-(2-tetrahydrofuroyl)piperazine-1-ylcarbamido!benzonitrile (IV)

(3,4-Dimethoxy-6-cyanoaniline-1-ylformamide (2.75 g, 12.5 mmol) (II) and4-(2-tetrahydrofuroyl)piperazine (2.56 g, 13.9 mmol) (III) are suspendedin 25 mL dry dichloroethane and the mixture is refluxed for 3 hours.

Water (30 mL) is added and the mixture is stirred at room temperaturefor 15 minutes. The layers are separated and the aqueous phase isfurther extracted with five portions of dichloroethane (20 mL). Theorganic layer is concentrated and applied to a silica gel column (25cm×2.5 cm). It is then eluted with ethyl acetate initially and thepolarity is gradually increased with ethanol to a final solvent ratio of80:20. Fractions containing the product (TLC: 80:20ethylacetate:methanol, R_(f) =0.5) are combined and the solventevaporated. The pure product is crystallized from a small volume ofethyl acetate as light yellow needles (1.18 g, 25% yield).

¹ H nmr (CDCl₃) d 7.35 (s, 1H, ArH, C-2); 7.10 (bs, 1H, NH; 6.85 (s, 1H,ArH, C-5); 4.58 (t, J=7.0 Hz, 1H, CH, C-2 (tetrahydrofuroyl)); 3.89 (s,3H, OCH₃); 3.80 (s, 3H, OCH₃); 4.11-3.18 (m, 10H, CH₂ 's (C-2, C-3, C-5,C-6 (piperazinyl), C-5 (tetrahydrofuroyl))); 2.22-1.49 (m, 4H, CH₂ 's(C-3, C-4 (tetrahydrofuroyl))).

EXAMPLE 6 2-4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline(VII)

The reaction mixture of Example 3 is cooled to 20° C. (after the threehour reflux). POCl₃ (2.11 g, 13.75 mmol) is added and the resultingsolution is heated to 70° C. and maintained for thirty minutes. Thereaction mixture is removed from the heat and allowed to cool to roomtemperature. Compound V is the result!. Anhydrous, NH₃ gas is moderatelypurged through the reaction mixture and the internal temperature isallowed to rise independently to a maximum temperature (70° C.-80° C.).When the internal temperature drops below the previously attainedmaximum temperature, the reaction mixture is slowly heated to 100° C.(alternatively (NH₄)₂ CO₃ can be used as a source of ammonia). Thereaction mixture is cooled to 60° C. and then vacuum distilled to aminimum volume. The residual pyridine is azeotroped off with smallamounts of water. Water (10 mL) and n-butanol (30 mL) are added to theaqueous solution and the mixture is heated to 60° C. The warm mixture isbasified to pH-10.0 with dropwise addition of 10% NaOH. The layers areseparated and the aqueous phase is further extracted with three portions(20 mL) of n-butanol. The organic extractions are combined and filteredthrough a bed of celite. The filtrate is dried over Na₂ SO₄,concentrated under reduced pressure and applied to a silica gel column(35 cm×5 cm). It is then eluted initially with ethyl acetate and thepolarity is gradually increased with ethanol to a final solvent ratio of80:20. Fractions containing the product (TLC: 80:20 ethylacetate:methanol, R_(f) =0.37) are combined and concentrated underreduced pressure. The pure product is crystallized from a minimum volumeof ethyl acetate as white crystals (3.02 g, 67% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 7 2-4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline(VII)

The reaction mixture of Example 3 is cooled to 20° C. (after the threehour reflux). PCl₅ (3.90 g, 18.75 mmol) is added and the resultingsolution is heated to 80° C. and maintained for thirty minutes. Thereaction mixture is removed from the heat and allowed to cool to roomtemperature. Compound V is the result!, Anhydrous, NH₃ gas is moderatelypurged through the reaction mixture and the internal temperature isallowed to rise independently to a maximum temperature (70° C.-80° C.).When the internal temperature drops below the previously attainedmaximum temperature, the reaction mixture is slowly heated to 100° C.(alternatively (NH₄)₂ CO₃ can be used as a source of ammonia). Thereaction mixture is cooled to 60° C. and then vacuum distilled to aminimum volume. The residual pyridine is azeotroped off with smallamounts of water. Water (10 mL) and n-butanol (30 mL) are added to theaqueous solution and the mixture is heated to 60° C. the warm mixture isbasified to pH-10.0 with dropwise addition of 10% NaOH. The layers areseparated and the aqueous phase is further extracted with three portions(20 mL) of n-butanol. The organic extractions are combined and filteredthrough a bed of celite. The filtrate is dried over Na₂ SO₄,concentrated under reduced pressure and applied to a silica gel column(35 cm×5 cm). It is then eluted initially with ethyl acetate and thepolarity is gradually increased with ethanol to a final solvent ratio of80:20. Fractions containing the product (TLC: 80:20 ethylacetate:methanol, R_(f) =0.37) are combined and concentrated underreduced pressure. The pure product is crystallized from a minimum volumeof ethyl acetate as white crystals (2.78 g, 59% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃): 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))): 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 8 2-4-(2-Tetrahydrofuroylpiperazine-1-yl!-4-amino-6,7-dimethoxyquinazoline(VII)

The reaction mixture of Example 3 is cooled to 20° C. (after the threehour reflux). P₂ O₅ (2.66 g, 18.75 mmol) is added and the resultingsolution is heated to 80° C. and maintained for thirty minutes. Thereaction mixture is removed from the heat and allowed to cool to roomtemperature. Compound V is the result!. Anhydrous, NH₃ gas is moderatelypurged through the reaction mixture and the internal temperature isallowed to rise independently to a maximum temperature (70° C.-80° C).When the internal temperature drops below the previously attainedmaximum temperature, the reaction mixture is slowly heated to 100° C.(alternatively (NH₄)₂ CO₃ can be used as a source of ammonia). Thereaction mixture is cooled to 60° C. and the vacuum distilled to aminimum volume. The residual pyridine is azeotroped off with smallamounts of water. Water (10 mL) and n-butanol (30 mL) are added to theaqueous solution and the mixture is heated to 60° C. The warm mixture isbasified to pH-10.0 with dropwise of 10% NaOH. The layers are separatedand the aqueous phase is further extracted with three portions (20 mL)of n-butanol. The organic extracts are combined and filtered through abed of celite. The filtrate is dried over Na₂ SO₄, concentrated underreduced pressure and applied to a silica gel column (35 cm×5 cm). It isthen eluted initially with ethyl acetate and the polariyy is graduallyincreased with ethanol to a final solvent ratio of 80:20. Fractionscontaining the product (TLC : 80:20 ethyl acetate:methanol, R_(f) =0.37)are combined and concentrated under reduced pressure. The pure productis crystallized from a minimum volume of ethyl acetate as white crystals(0.71 g, 15% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 9 2-4-(2-Tetrahydrofuroylpiperazine)-1-y!l-4-amino-6,7-dimethoxyquinazoline(VII)

The reaction mixture of Example 3 is cooled to 20° C. (after the threehour reflux). P-toluenesulfonyl chloride (3.57 g, 18.75 mmol) is addedand the resulting solution is heated to reflux and maintained for ninetyminutes. The reaction mixture is removed from the heat and allowed tocool to room temperature. Compound V is the result!, Anhydrous NH₃ gasis moderately purged through the reaction mixture and the internaltemperature is allowed to rise independently to a maximum temperature(70° C.-80° C). When the internal temperature drops below the previouslyattained maximum temperature, the reaction mixture is slowly heated to100° C. (alternatively (NH₄)₂ CO₃ can be used as a source of ammonia).The reaction mixture is cooled to 60° C. and the vacuum distilled to aminimum volume. The residual pyridine is azeotroped off with smallamounts of water. Water (10 mL) and n-butanol (30 mL) are added to theaqueous solution and the mixture is heated to 60° C. The warm mixture isbasified to pH-10.0 with dropwise addition of 10% NaOH. The layers areseparated and the aqueous phase is further extracted with three portions(20 mL) of n-butanol. The organic extracts are combined and filteredthrough a bed of celite. The filtrate is dried over Na₂ SO₄,concentrated under reduced pressure and applied to a silica gel column(35 cm×5 cm). It is then eluted initially with ethyl acetate and thepolarity is gradually increased with ethanol to a final solvent ratio of80:20. Fractions containing the product (TLC :80:20 ethylacetate:methanol, R_(f) =0.37) are combined and concentrated underreduced pressure. The pure product is crystallized from a minimum volumeof ethyl acetate as white crystals (0.23 g,5% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 10 2-4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline(VII)

Under an inert atmosphere (N₂) and anhydrous conditions3,4-dimethoxy-6-cyanoanaline-1-ylformamide (2.21 g, 10 mmol) issuspended in dry pyridine (10 mL). With vigorous stirring POCl₃ (1.9 g,12 mmol) is added and the solution is heated to 60° C. and maintainedfor fifteen minutes. 4-(2-Tetrahydrofuroyl)piperazine (2.20 g, 12 mmol)is added and the reaction mixture is brought to reflux and maintainedfor two hours. Compound V is produced but not isolated!. The solvent isdistilled off to a minimum volume and the residual pyridine isazeotroped off with small portions of water. Water is added to theaqueous mixture to bring the reaction volume to 30 mL. Chloroform (30mL) is then added to the aqueous solution and with vigorous stirring themixture is basified to pH=10 with dropwise addition of 10% NaOH. Thelayers are separated and the aqueous phase is further extracted withfour portions (10 mL) of chloroform. The organic extracts are combinedand filtered through a bed of celite. The filtrate is dried over Na₂SO₄, concentrated under reduced pressure and applied to a silica gelcolumn (25 cm×2.5 cm). It is then eluted initially with ethyl acetateand the polarity is gradually increased with ethanol to a final solventratio of 80:20. Fractions containing the product (TLC: 80:20 ethylacetate:methanol, R_(f) =0.37) are combined and concentrated underreduced pressure. The pure product is crystallized from a minimum volumeof ethyl accetate as white crystals (0.77 g, 20% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s. 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 11 2-4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline(VII)

Under an inert atmosphere (N₂) and anhydrous conditions3,4-dimethoxy-6-cyanoanaline-1-ylformamide (2.21 g, 10 mmol) issuspended in dry pyridine (10 mL). With vigorous stirring PCl₅ (2.50 g,12 mmol) is added and the solution is heated to 60° C. and maintainedfor fifteen minutes. 4-(2-Tetrahydrofuroyl)piperazine (2.20 g, 12 mmolis added and the reaction mixture is brought to reflux and maintainedfor two hours. Compound V was produced but not isolated!. The solvent isvacuum distilled off to a minimum volume and the residual pyridine isazeotroped off with small portions of water. Water is added to theaqueous mixture to bring the reaction volume to 30 mL. Chloroform (30mL) is then added to the aqueous solution and with vigorous stirring themixture is basified to pH=10 with drowise addition of 10% NaOH. Thelayers are separated and the aqueous phase is further extracted withfour portions (10 mL) of chloroform. The organic extracts are combinedand filtered through a bed of celite. The filtrate is dried over Na₂SO₄, concentrated under reduced pressure and applied to a silica gelcolumn (25 cm×2.5 cm). It is then eluted initially with ethyl acetateand the polarity is gradually increased with ethanol to a final solventratio of 80:20. Fractions containing the product (TLC: 80:20 ethylacetate:methanol, R_(f) =0.37) are combined and concentrated underreduced pressure. The pure product is crystallized from a minimum volumeof ethyl acetate as white crystals (0.60 g, 16% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 12 2-4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline(VII)

3,4-Dimethoxy-6-cyanoanaline-1-ylformamide (2.21 g, 10 mmol) issuspended in dry pyridine (10 mL) and with stirring p-toluenesulfonylchloride (2.5 g, 13 mmol) is added portionwise. The reaction mixture isheated on a water bath (60° C.) until complete dissolution is achieved4-(2-Tetrahydrofuroyl)piperazine (2.20 g, 12 mmol) is added and themixture is brought to reflux and maintained for two hours. The solventis vacuum distilled off to a minimum volume and the residual pyridine isazeotroped off with small portions of water. Water is added to theaqueous mixture to bring the reaction volume to 30 mL. Chloroform (30mL) is then added to the aqueous solution and with vigorous stirring themixture is basified to pH=10 with dropwise addition of 10% NaOH. Thelayers are separated and the aqueous phase is further extracted withfour portions (10 mL) of chloroform. The organic extracts are combinedand filtered through a bed of celite. The filtrate is dried over Na₂SO₄, concentrated under reduced pressure and applied to a silica gelcolumn (25 cm×2.5 cm). It is then eluted initially with ethyl acetateand the polarity is gradually increased with ethanol to a final solventratio of 80:20. Fractions containing the product (TIC: 80:20 ethylacetate:methanol, R_(f) =0.37) are combined and concentrated underreduced pressure. The pure product is crystallized from a minimum volumeof ethyl acetate as white crystals (0.53 g, 14% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 13 2-4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline(VII)

3,4-dimethoxy-6-cyanoanaline-1-ylformamide (2.21 g, 10 mmol) issuspended in dry dichloroethane (10 mL) and triethylamine (2.0 g, 20mmol) is added and the suspension is stirred for 10 minutes.P-toluenesulfonyl chloride (2.5 g, 13 mmol) is added portionwise and thereaction mixture is heated to reflux and maintained for one hour. Themixture is allowed to cool to room temperature and4-(2-Tetrahydrofuroyl)piperazine (2.20 g, 12 mmol) is added and themixture is brought to reflux and maintained for two hours. Water (30 mL)is added and with vigorous stirring the mixture is basified to pH:10with dropwise addition of 10% NaOH. The layers are separated and theaqueous phase is further extracted with four portions (10 mL) ofdichloroethane. The organic extracts are combined and filtered through abed of celite. The filtrate is dried over Na₂ SO₄, concentrated underreduced pressure and applied to a silica gel column (25 cm×2.5 cm). Itis then eluted initially with ethyl acetate and the polarity isgradually increased with ethanol to a final solvent ratio of 80:20.Fractions containing the product (TLC: 80:20 ethyl acetate:methanol,R_(f) :0.37) are combined and concentrated under reduced pressure. Thepure product is crystallized from a minimum volume of ethyl acetate aswhite crystals (0.38 g, 10% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃): 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH,₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 14 2-4-(2-Tetrahydrofuroylpiperazine)-1yl!-4-amino-6,7-dimethoxyquinazoline(VII)

4-(2-Tetrahyrofuroyl)piperazine-1-yl-formamide (2.27 g, 10 mmol) issuspended in dichloroethane (15 mL) and heated until total dissolutionis achieved. Triethylamine (2.0 g, 20 mmol) is added and the solution isstirred for 5 minutes. P-toluenesulfonyl chloride (3.92 g, 20 mmol) isadded and the reaction mixture is heated to reflux and maintained for 3hours. Compound X is produced. 3,4-Dimethoxyanthralinonitrile (1.78 g,10 mmol) is added and reflux is continued for an additional 24 hours.Compound VI is the result!. Water (30 mL) is added and with vigorousstirring the mixture is basified to pH=10 with dropwise addition of 10%NaOH. The layers are separated and the aqueous phase is furtherextracted with four portions (10 mL) of dichloroethane. The organicextracts are combined and filtered through a bed of celite. The filtrateis dried over Na₂ SO₄, concentrated under reduced pressure and appliedto a silica gel column (25 cm×2.5 cm). It is then eluted initially withethyl acetate and the polarity is gradually increased with ethanol to afinal solvent ratio of 80:20. Fractions containing the product (TLC:80:20 ethyl acetate:methanol, R_(f) =0.37) are combined and concentratedunder reduced pressure. The pure product is crystallized from a minimumvolume of ethyl acetate as white crystals (0.76 g, 20% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)), 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m. 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))), 2.39-1.75 (m. 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 15 2- 4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline (VII)

A mixture of 3,4-dimethoxyanthranilonitrile (7.91 g, 44.5 mmol),4-(2-Tetrahyrofuroyl)piperazine-1-yl-formamide (10.1 g, 44.5 mmol) andP₂ O₅ (32.0 g, 225 mmol) in dry pyridine (50 mL) is refluxed withstirring for 2.5 hours. The reaction mixture is then allowed to cool toroom temperature over a 1 hour period and then poured into a vesselcontaining sodium bicarbonate (60 g). The reaction vessel is then washedwith four portions of water (50 mL) which are combined with bicarbonatemixture. The mixture is stirred for 30 minutes and filtered. Thefiltrate is then extracted with four portions of chloroform (100 ml).The organic layers are combined, dried over Na₂ SO₄ and concentratedunder reduced pressure. The orange oil obtained is applied to a silicagel column (25 cm×2.5 cm) and is eluted initially with ethyl acetate andthe polarity is gradually increased with ethanol to a final solventratio of 80:20. Fractions containing the product (TLC: 80:20 ethylacetate: methanol, R_(f) =0.37) are combined and concentrated underreduced pressure. The pure product is crystallized from a minimum volumeof ethyl acetate as white crystals (2.05 g, 12% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 16 2-4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline(VII)

A mixture of 3,4-dimethoxy-6-cyanoaniline-1-ylformamide (10.6 g, 48mmol) (II), 4-(2-tetrahydrofuroyl) piperazine (8.8 g, 48 mmol) (III) andP₂ O₅ (36 g. 250 mmol) in dry pyridine (100 mL) is refluxed withstirring for 4 hours. The reaction mixture is then allowed to cool toroom temperature over a 1 hour period and then poured into a vesselcontaining sodium bicarbonate (60 g). The reaction vessel is then washedwith four portions of water (50 mL) which are combined with bicarbonatemixture. The mixture is stirred for 30 minutes and filtered. Thefiltrate is then extracted with four portions of chloroform (100 ml).The organic layers are combined, dried over Na₂ SO₄ and concentratedunder reduced pressure. The orange off obtained is applied to a silicagel column (25 cm×2.5 cm) and is eluted initially with ethyl acetate andthe polarity is gradually increased with ethanol to a final solventratio of 80:20. Fractions containing the product (TLC: 80:20 ethylacetate: methanol, R_(f) :0.37) are combined and concentrated underreduced pressure. The pure product is crystallized from a minimum volumeof ethyl acetate as white crystals (1.85 g, 10% yield).

¹ H nmr (CDCl₃) d 6.98 (s. 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 17 2- 4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline(VII)

4-(2-Tetrahyrofuroyl)piperazine-1-yl-formamide (2.27 g, 10 mmol) issuspended in dichloroethane (15 mL) and heated until total dissolutionis achieved. Triethylamine (2.0 g, 20 mmol is added and the solution isstirred for 5 minutes. Methanesulfonyl chloride (2.29 g, 20 mmol) isadded and the reaction mixture is heated to reflux and maintained for 1hour. 3,4-Dimethoxyanthranilonitrile (1.78 g, 10 mmol is added andreflux is continued for an additional 24 hours. Water (30 mL) is addedand with vigorous stirring the mixture is basified to pH:10 withdropwise addition of 10% NaOH. The layers are separated and the aqueousphase is further extracted with four portions (10 mL) of dichloroethane.The organic extractions are combined and filtered through a bed ofcelite. The filtrate is dried over Na₂ SO₄, concentrated under reducedpressure and applied to a silica gel column (25 cm×2.5 cm). It is theneluted initially with ethyl acetate and the polarity is graduallyincreased with ethanol to a final solvent ratio of 80:20. Fractionscontaining the product (TLC: 80:20 ethyl acetate:methanol, R_(f) =0.37)are combined and concentrated under reduced pressure. The pure productis crystallized from a minimum volume of ethyl acetate as white crystals(0.83 g, 22% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃): 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 18 2-4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline(VII)

4-(2-Tetrahyrofuroyl)piperazine-1-yl-formamide (2.27 g, 10 mmol) issuspended in dry pyridine (10 mL) and with stirring POCl₃ (1.8 g, 12mmol) is added and the reaction mixture is stirred for an additional tenminutes. 3,4-Dimethoxyanthranilonitrile (1.78 g, 10 mmol) is added andthe mixture is brought to reflux and maintained for three hours. Thesolvent is vacuum distilled off to a minimum volume and the residualpyridine is azeotroped off with small portions of water. Water is addedto the aqueous mixture to bring the reaction volume to 30 mL. Chloroform(30 mL) is then added to the aqueous solution and with vigorous stirringthe mixture is basified to pH=10 with dropwise addition of 10% NaOH. Thelayers are separated and the aqueous phase is further extracted withfour portions (10 mL) of chloroform. The organic extracts are combinedand filtered through a bed of celite. The filtrate is dried over Na₂SO₄, concentrated under reduced pressure and applied to a silica gelcolumn (25 cm×2.5 cm). It is then eluted initially with ethyl acetateand the polarity is gradually increased with ethanol to a final solventratio of 80:20. Fractions containing the product (TLC : 80:20 ethylacetate:methanol, R_(f) =0.37) are combined and concentrated underreduced pressure. The pure product is crystallized from a minimum volumeof ethyl acetate as white crystals (0.26 g, 7% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))): 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 19 2- 4-(2-Tetrahydrofuroylpiperazine-1-yl!-4-amino-6,7-dimethoxyquinazoline (VII)

4-(2-Tetrahyrofuroyl)piperazine-1-yl-formamide (2.27 g, 10 mmol) issuspended in dichloroethane (15 mL) and with stirring POCl₃ (1.8 g, 12mmol) is added and the reaction mixture is stirred for an additional tenminutes. 3,4-Dimethoxyanthranilonitrile (1.78 g. 10 mmol) is added andthe mixture is brought to reflux and maintained for 24 hours. Water (30mL) is added and with vigorous stirring the mixture is basified to pH:10with dropwise addition of 10% NaOH. The layers are separated and theaqueous phase is further extracted with four portions (10 mL) ofdichloroethane. The organic extracts are combined and filtered through abed of celite. The filtrate is dried over Na₂ SO₄, concentrated underreduced pressure and applied to a silica gel column (25 cm×2.5 cm). Itis then eluted initially with ethyl acetate and the polarity isgradually increased with ethanol to a final solvent ratio of 80:20.Fractions containing the product (TLC: 80:20 ethyl acetate:methanol,R_(f) =0.45) are combined and concentrated under reduced pressure. Thepure product is crystallized from a minimum volume of ethyl acetate aswhite crystals (0.30 g, 8% yield);

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2. C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 20 2- 4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazoline (VII)

4-(2-Tetrahyrofuroyl)piperazine-1-yl-formamide (2.27 g, 10 mmol) issuspended in dichloroethane (15 mL) and with stirring, triethylamine(1.2 g, 12 mmol) is added and the reaction mixture is stirred for 15minutes. POCl₃ (1.8 g. 12 mmol) is added and the mixture is heated toreflux and maintained for ten minutes. The reaction is cooled to roomtemperature and 3,4-dimethoxyanthranilonitrile (1.78 g, 10 mmol) isadded and the mixture is brought to reflux and maintained for 24 hours.Water (30 mL) is added and with vigorous stirring the mixture isbasified to pH=10 with dropwise addition of 10% NaOH. The layers areseparated and the aqueous phase is further extracted with four portions(10 mL) of dichloroethane. The organic extracts are combined andfiltered through a bed of celite. The filtrate is dried over Na₂ SO₄,concentrated under reduced pressure and applied to a silica gel column(25 cm×2.5 cm). It is then eluted initially with ethyl acetate and thepolarity is gradually increased with ethanol to a final solvent ratio of80:20. Fractions containing the product (TLC : 80:20 ethylacetate:methanol, R_(f) =0.37) are combined and concontrated underreduced pressure. The pure product is crystallized from a minimum volumeof ethyl acetate as white crystals (0.35 g, 9.2% yield).

¹ H nmr (CDCl₃) d 6.98 (s, 1H, ArH, C-5); 5.52 (bs, 2H, NH₂); 4.82-4.50(m, 1H, CH, C-2 (tetrahydrofuroyl)); 3.98 (s, 3H, OCH₃); 3.90 (s, 3H,OCH₃); 4.10-3.42 (m, 10H, CH₂ 's (C-2, C-3, C-5, C-6 (piperazinyl), C-5(tetrahydrofuroyl))); 2.39-1.75 (m, 4H, CH₂ 's (C-3, C-4(tetrahydrofuroyl))).

EXAMPLE 21 2-4-(2-Tetrahydrofuroylpiperazine)-1-yl!-4-amino-6,7-dimethoxyquinazolineHydrochloride Dihydrate(XI)

Terazosin free base (VII, 3.87 g, 10 mmol) was suspended in 20 mL hotisopropanol and concentrated hydrochloric acid (5 mL) was added. Asolution was obtained which was concentrated to dryness under reducedpressure. Isopropanol (20 mL) was then added and the resultingsuspension was brought to reflux and then cooled to room temperature.The slurry was filtered and washed with a small volume of isopropanol.Yield 4.1 g (90% yield), mp 271-273.

As many changes can be made to the examples without departing from thescope of the invention, it is intended that all material containedherein be interpreted as illustrative of the invention and not in alimiting sense.

The embodiments of the invention in which an exclusive property orprivilege is claimed are as follows:
 1. The process of reacting compound(VIII) of the formula ##STR76## to give compound (VI) of the formula##STR77## wherein Y is (i) hydrogen or wherein NY is (ii) a compound ofthe formula ##STR78## and when Y is H, compound (VIII) is reacted withcompound (III) of the formula ##STR79## and when NY is (ii), compound(VIII) is reacted with NH₃.
 2. The process of claim 1 wherein NY is (ii)and the reaction comprises reacting:intermediate (V) of the formula##STR80## in the presence of NH₃ to give compound (VI) of the formula##STR81##
 3. The process of claim 2 further comprising closing a ringin:compound (VI) of the formula ##STR82## to give compound (VII) of theformula ##STR83##
 4. The process of claim 2 or 3 further comprisingreacting compound (VI) or compound (VII) thereof to produce a medicineselected from the group consisting of Terazosin, Prazosin, Doxazosin,Tiodazosin, Trimazosin, Quinazosin or Bunazosin.
 5. A process comprisingreacting:compound (V') of the formula ##STR84## in the presence of NH₃to give compound (VI') of the formula ##STR85## wherein O--EP is aleaving group substitutable by --NH₂ or an amine and wherein EP isselected from the group consisting of POCL₃, PCl₅, P₂ O₅, TsCl andwherein R is tetrahydrofuryl, furyl or 1-4-benzodioxan-2-yl.
 6. Theprocess of claim 5 wherein R is tetrahydrofuryl further comprisingreacting compound (VI') to produce Terazosin or a form thereof.
 7. Theprocess of claim 5 wherein R is furyl further comprising reactingcompound (VI') to produce Prazosin.
 8. The process of claim 5 wherein Ris 1,4-benzodioxan-2-yl, further comprising reacting compound (VI') toproduce Doxazosin.
 9. The process of claim 5 where R is tetrahydrofurylfurther comprising closing the ring in:compound (VI") of the formula##STR86## to give compound (VII") of the formula ##STR87##
 10. Theprocess of claim 9 further comprising reacting compound (VII") toproduce Terazosin hydrochloride dihydrate.
 11. A process comprisingclosing a ring in:compound (VI') of the formula ##STR88## to givecompound (VII') of the formula ##STR89## wherein R is selected fromfuryl and 1,4-benzodioxan-2-yl.
 12. The process of claim 11 wherein R isfuryl further comprising reacting compound (VII') to produce Prazosin.13. The process of claim 11 wherein R is 1,4-benzodioxan-2-yl, furthercomprising reacting compound (VII') to produce Doxazosin.
 14. Theprocess of claim 1 wherein Y is H and the reaction comprisesreacting:intermediate (VIII) of the formula ##STR90## to give compound(VI) of the formula ##STR91## to give compound (VI) of the formula##STR92##
 15. The process of claim 14 further comprising closing a ringin:compound (VI) of the formula ##STR93## to give compound (VII) of theformula ##STR94##
 16. The process of claim 14 or 15 further comprisingreacting compound (VI) or compound (VII) thereof to produce a medicineselected from Terazosin, Prazosin, Doxazosin, Tiodazosin, Trimazosin,Quinazosin or Bunazosin.
 17. The process of claim 15 further comprisingreacting:compound (II') of the formula ##STR95## in the presence of EPto give the intermediate (VIII') of the formula ##STR96## wherein O--EPis a leaving group substitutable by --NH₂ or an amine.
 18. The processof claim 17 further comprising reacting compound (VIII') to produce acompound selected from Terazosin, Terazosin hydrochloride dihydrate,Prazosin or Doxazosin.
 19. The process of claim 14 comprising:reactingcompound (VIII') of the formula ##STR97## with compound (III") of theformula ##STR98## to give compound (VI") of the formula ##STR99##wherein O--EP is a leaving group substitutable by --NH₂ and where R₁ andR₂ are methyl and R is selected from furyl, tetrahydrofuryl and1,4-benzodioxan-2-yl.
 20. The process of claim 19 further comprisingreacting compound (VI") to produce a product selected from Terazosin,Terazosin hydrochloride dihydrate, Prazosin or Doxazosin.